The Study
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
This study is like a big experiment where some people get a new medicine and some get a fake pill, and we compare them. Because the groups were chosen by chance and no one knew who got the real medicine, we can be very sure that the medicine caused the improvements in the liver. So we can say 'the medicine helps' not just 'it might help'.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
A study tested a drug called semaglutide (used for diabetes and weight loss) in people with a serious fatty liver disease called MASH. They gave weekly injections to 800 patients.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 588 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These improvements are significant because MASH can lead to cirrhosis and liver failure.
- 2The drug seems to help both the inflammation and scarring, and the weight loss likely contributes.
- 3After 72 weeks, 62.9% of those on semaglutide had no signs of liver inflammation (vs 34.3% on placebo), and 36.8% had less liver scarring (vs 22.4%).
- 4People lost about 10.5% of their body weight.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The New England journal of medicine
Year
2025
Authors
Arun J. Sanyal, Philip N. Newsome, Iris Kliers, L. Østergaard, Michelle T. Long, M. Kjær, Anna M G Cali, Elisabetta Bugianesi, M. Rinella, Michael Roden, Vlad Ratziu
Related Content
Claims (5)
A weekly injection of semaglutide (2.4 mg) reduces liver scarring in about 37% of people with MASH and moderate liver fibrosis, compared to 22% receiving a placebo, without worsening liver fat inflammation. The difference of 14.4 percentage points is statistically significant.
Semaglutide reduces body weight by 10.5% in people with MASH and liver fibrosis stage 2 or 3, compared to a 2.0% reduction with placebo, at 72 weeks. This weight loss is large enough to improve liver health.
Patients with MASH and liver fibrosis who received weekly semaglutide injections had a 62.9% rate of steatohepatitis resolution without worsening fibrosis, significantly higher than the 34.3% rate in the placebo group over 72 weeks.
Semaglutide, a drug injected once a week, improves both liver inflammation and scarring in about one-third of people with a type of fatty liver disease called MASH who have moderate liver fibrosis. This effect is twice as common as with a placebo.
Patients with MASH and moderate liver fibrosis who take weekly semaglutide injections have more gastrointestinal side effects like nausea and diarrhea than those taking a placebo. However, the rate of serious adverse events is not higher with semaglutide.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.